Yindan Jiedu Granules, a Traditional Chinese Medicinal Formulation, as a Potential Treatment for Coronavirus Disease 2019
Background:YindanJiedu Granules (YDJDG) have been newly prescribed as a Chinese herbal formula. This study aimed to compare the efficacy of YDJDG and lopinavir-ritonavir in the treatment of coronavirus disease 2019 (COVID-19).Methods: Overall, 131 patients with COVID-19 were included in this study....
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-02-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2020.634266/full |
| _version_ | 1828967650189901824 |
|---|---|
| author | Jingyuan Liu Yuyong Jiang Yao Liu Lin Pu Chunjing Du Yuxin Li Xiaojing Wang Jie Ren Wei Liu Zhiyun Yang Zhihai Chen Rui Song Wen Xie Xianbo Wang |
| author_facet | Jingyuan Liu Yuyong Jiang Yao Liu Lin Pu Chunjing Du Yuxin Li Xiaojing Wang Jie Ren Wei Liu Zhiyun Yang Zhihai Chen Rui Song Wen Xie Xianbo Wang |
| author_sort | Jingyuan Liu |
| collection | DOAJ |
| description | Background:YindanJiedu Granules (YDJDG) have been newly prescribed as a Chinese herbal formula. This study aimed to compare the efficacy of YDJDG and lopinavir-ritonavir in the treatment of coronavirus disease 2019 (COVID-19).Methods: Overall, 131 patients with COVID-19 were included in this study. In addition to standard care, 60 of these patients received YDJDG (YDJDG group) and 71 received lopinavir-ritonavir (lopinavir-ritonavir group). Propensity score matching (PSM) was used to match the characteristics of individuals in the two groups, while the Kaplan-Meier method was used to compare the proportion recovery observed.Results: Cox analysis revealed that YDJDG and CD4 ≥ 660 cells/µL were independent predictive factors of proportion recovery. At baseline, disease types differed between the YDJDG and lopinavir-ritonavir treatment groups. Furthermore, no significant adverse effects or toxicities relevant to YDJDG were observed. The median recovery time was 21 days in the YDJDG group and 27 days in the lopinavir-ritonavir group. After PSM (1:1), 50 patient pairs, YDJDG vs. lopinavir-ritonavir, were analyzed. In the YDJDG group, the proportion of recovered patients was remarkably higher than that observed in the lopinavir-ritonavir group (p = 0.0013), especially for those presenting mild/moderate disease type and CD4 < 660 cells/µL. In the YDJDG group, the mean duration of fever and pulmonary exudative lesions was significantly shorter than that observed in the lopinavir-ritonavir group (p = 0.0180 and p = 0.0028, respectively).Conclusion: YDJDG reveals the potential to hasten the recovery period in COVID-19 patients with mild/moderate disease type or CD4 < 660 cells/µL by shortening the mean duration of fever and pulmonary exudative lesions. |
| first_indexed | 2024-12-14T11:55:01Z |
| format | Article |
| id | doaj.art-1e93aa6bdf864635bfd84f19d96c2374 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-14T11:55:01Z |
| publishDate | 2021-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-1e93aa6bdf864635bfd84f19d96c23742022-12-21T23:02:08ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-02-011110.3389/fphar.2020.634266634266Yindan Jiedu Granules, a Traditional Chinese Medicinal Formulation, as a Potential Treatment for Coronavirus Disease 2019Jingyuan Liu0Yuyong Jiang1Yao Liu2Lin Pu3Chunjing Du4Yuxin Li5Xiaojing Wang6Jie Ren7Wei Liu8Zhiyun Yang9Zhihai Chen10Rui Song11Wen Xie12Xianbo Wang13Department of Critical Care Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, ChinaCenter of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, ChinaCenter of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, ChinaDepartment of Critical Care Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, ChinaDepartment of Critical Care Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, ChinaCenter of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, ChinaCenter of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, ChinaCenter of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, ChinaDepartment of Pharmacy, Beijing Shijitan Hospital, Capital Medical University, Beijing, ChinaCenter of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, ChinaCenter of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, ChinaCenter of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, ChinaLiver Diseases Center, Beijing Ditan Hospital, Capital Medical University, Beijing, ChinaCenter of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, ChinaBackground:YindanJiedu Granules (YDJDG) have been newly prescribed as a Chinese herbal formula. This study aimed to compare the efficacy of YDJDG and lopinavir-ritonavir in the treatment of coronavirus disease 2019 (COVID-19).Methods: Overall, 131 patients with COVID-19 were included in this study. In addition to standard care, 60 of these patients received YDJDG (YDJDG group) and 71 received lopinavir-ritonavir (lopinavir-ritonavir group). Propensity score matching (PSM) was used to match the characteristics of individuals in the two groups, while the Kaplan-Meier method was used to compare the proportion recovery observed.Results: Cox analysis revealed that YDJDG and CD4 ≥ 660 cells/µL were independent predictive factors of proportion recovery. At baseline, disease types differed between the YDJDG and lopinavir-ritonavir treatment groups. Furthermore, no significant adverse effects or toxicities relevant to YDJDG were observed. The median recovery time was 21 days in the YDJDG group and 27 days in the lopinavir-ritonavir group. After PSM (1:1), 50 patient pairs, YDJDG vs. lopinavir-ritonavir, were analyzed. In the YDJDG group, the proportion of recovered patients was remarkably higher than that observed in the lopinavir-ritonavir group (p = 0.0013), especially for those presenting mild/moderate disease type and CD4 < 660 cells/µL. In the YDJDG group, the mean duration of fever and pulmonary exudative lesions was significantly shorter than that observed in the lopinavir-ritonavir group (p = 0.0180 and p = 0.0028, respectively).Conclusion: YDJDG reveals the potential to hasten the recovery period in COVID-19 patients with mild/moderate disease type or CD4 < 660 cells/µL by shortening the mean duration of fever and pulmonary exudative lesions.https://www.frontiersin.org/articles/10.3389/fphar.2020.634266/fullCOVID-19herbal medicineYindan Jiedu granulesrecovery proportionfeverpulmonary exudative lesions |
| spellingShingle | Jingyuan Liu Yuyong Jiang Yao Liu Lin Pu Chunjing Du Yuxin Li Xiaojing Wang Jie Ren Wei Liu Zhiyun Yang Zhihai Chen Rui Song Wen Xie Xianbo Wang Yindan Jiedu Granules, a Traditional Chinese Medicinal Formulation, as a Potential Treatment for Coronavirus Disease 2019 Frontiers in Pharmacology COVID-19 herbal medicine Yindan Jiedu granules recovery proportion fever pulmonary exudative lesions |
| title | Yindan Jiedu Granules, a Traditional Chinese Medicinal Formulation, as a Potential Treatment for Coronavirus Disease 2019 |
| title_full | Yindan Jiedu Granules, a Traditional Chinese Medicinal Formulation, as a Potential Treatment for Coronavirus Disease 2019 |
| title_fullStr | Yindan Jiedu Granules, a Traditional Chinese Medicinal Formulation, as a Potential Treatment for Coronavirus Disease 2019 |
| title_full_unstemmed | Yindan Jiedu Granules, a Traditional Chinese Medicinal Formulation, as a Potential Treatment for Coronavirus Disease 2019 |
| title_short | Yindan Jiedu Granules, a Traditional Chinese Medicinal Formulation, as a Potential Treatment for Coronavirus Disease 2019 |
| title_sort | yindan jiedu granules a traditional chinese medicinal formulation as a potential treatment for coronavirus disease 2019 |
| topic | COVID-19 herbal medicine Yindan Jiedu granules recovery proportion fever pulmonary exudative lesions |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2020.634266/full |
| work_keys_str_mv | AT jingyuanliu yindanjiedugranulesatraditionalchinesemedicinalformulationasapotentialtreatmentforcoronavirusdisease2019 AT yuyongjiang yindanjiedugranulesatraditionalchinesemedicinalformulationasapotentialtreatmentforcoronavirusdisease2019 AT yaoliu yindanjiedugranulesatraditionalchinesemedicinalformulationasapotentialtreatmentforcoronavirusdisease2019 AT linpu yindanjiedugranulesatraditionalchinesemedicinalformulationasapotentialtreatmentforcoronavirusdisease2019 AT chunjingdu yindanjiedugranulesatraditionalchinesemedicinalformulationasapotentialtreatmentforcoronavirusdisease2019 AT yuxinli yindanjiedugranulesatraditionalchinesemedicinalformulationasapotentialtreatmentforcoronavirusdisease2019 AT xiaojingwang yindanjiedugranulesatraditionalchinesemedicinalformulationasapotentialtreatmentforcoronavirusdisease2019 AT jieren yindanjiedugranulesatraditionalchinesemedicinalformulationasapotentialtreatmentforcoronavirusdisease2019 AT weiliu yindanjiedugranulesatraditionalchinesemedicinalformulationasapotentialtreatmentforcoronavirusdisease2019 AT zhiyunyang yindanjiedugranulesatraditionalchinesemedicinalformulationasapotentialtreatmentforcoronavirusdisease2019 AT zhihaichen yindanjiedugranulesatraditionalchinesemedicinalformulationasapotentialtreatmentforcoronavirusdisease2019 AT ruisong yindanjiedugranulesatraditionalchinesemedicinalformulationasapotentialtreatmentforcoronavirusdisease2019 AT wenxie yindanjiedugranulesatraditionalchinesemedicinalformulationasapotentialtreatmentforcoronavirusdisease2019 AT xianbowang yindanjiedugranulesatraditionalchinesemedicinalformulationasapotentialtreatmentforcoronavirusdisease2019 |